Evidence Hub

Real-Time Image-Guided Ablative Prostate Cancer Radiation Therapy: Results from the TROG 15.01 SPARK Trial

P. Keall, D. Nguyen, R. O'Brien, E. Hewson, Helen L. Ball, P. Poulsen, J. Booth, P. Greer et al.

International Journal of Radiation Oncology, Biology, Physics, 2020

51 citations

Abstract

PURPOSE

Kilovoltage Intrafraction Monitoring (KIM) is a novel software platform implemented on standard radiation therapy systems enabling real-time image-guided radiation therapy (IGRT). In a multi-institutional prospective trial, we investigated whether real-time IGRT improved the accuracy of the dose prostate cancer patients received during radiation therapy.

METHODS AND MATERIALS

Forty-eight patients with prostate cancer were treated with KIM-guided Stereotactic Ablative Radiation Therapy (SABR) with 36.25 Gy in five fractions. During KIM-guided treatment the prostate motion was corrected for by either beam gating with couch shifts or multileaf collimator tracking. A dose reconstruction method was used to evaluate the dose delivered to the target and organs at risk with and without real-time IGRT. Primary outcome was the effect of real-time IGRT on dose distributions. Secondary outcomes included patient-reported outcomes and toxicity.

RESULTS

Motion correction occurred in ≥1 treatment for 88% of patients (42/48) and 51% of treatments (121/235). With real-time IGRT, no treatments had prostate CTV D98% dose 5% less than planned. Without real-time IGRT, 13 treatments (5·5%) had prostate CTV D98% doses 5% less than planned. The prostate CTV D98% dose with real-time IGRT was closer to the plan by an average of 1·0% (range -2·8% to 20·3%). Patient outcomes show no change in the 12-month patient reported outcomes compared with baseline and no grade ≥3 GU or GI toxicities.…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free